• 1. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Introduction to 6-(Azepan-2-yl)quinoline (CAS No. 904816-03-1)

6-(Azepan-2-yl)quinoline, identified by the Chemical Abstracts Service Number (CAS No.) 904816-03-1, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic molecule combines the structural features of quinoline and azepane, making it a versatile scaffold for the development of novel therapeutic agents. The unique arrangement of nitrogen atoms in its structure imparts distinctive electronic and steric properties, which are highly valued in drug design.

The quinoline moiety, a well-known pharmacophore, has a rich history in medicinal chemistry, with several clinically approved drugs derived from this scaffold. Notably, derivatives of quinoline have demonstrated efficacy in treating malaria, tuberculosis, and certain types of cancer. The introduction of the azepan-2-yl group into the quinoline framework introduces conformational flexibility and alters the pharmacokinetic profile of the compound. This modification has been strategically employed to enhance binding affinity and reduce toxicity, making 6-(Azepan-2-yl)quinoline a promising candidate for further investigation.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 6-(Azepan-2-yl)quinoline and biological targets. Studies have revealed that the compound can effectively modulate enzyme activity and receptor binding, suggesting its potential in addressing various diseases. For instance, research has indicated that this molecule may exhibit inhibitory effects on kinases and other enzymes involved in cancer progression. Additionally, its ability to cross the blood-brain barrier has raised interest in its potential applications in neurodegenerative disorders.

The synthesis of 6-(Azepan-2-yl)quinoline involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Modern synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions, have been instrumental in optimizing the production process. These techniques not only improve efficiency but also minimize waste, aligning with the principles of green chemistry. The growing emphasis on sustainable practices in pharmaceutical manufacturing makes the development of such compounds particularly relevant.

In vitro and in vivo studies have provided valuable insights into the pharmacological properties of 6-(Azepan-2-yl)quinoline. Preliminary results suggest that it exhibits significant antitumor activity by inhibiting key signaling pathways involved in cell proliferation and survival. Furthermore, its interaction with DNA has been studied to assess potential therapeutic effects against genetic disorders. The compound's stability under various physiological conditions also enhances its suitability for clinical applications.

The structural diversity offered by 6-(Azepan-2-yl)quinoline allows for extensive derivatization, enabling researchers to fine-tune its biological activity. By introducing different substituents at strategic positions within the molecule, new analogs with enhanced potency and selectivity can be generated. This flexibility is particularly advantageous in addressing complex diseases that require tailored therapeutic approaches. Collaborative efforts between academic institutions and pharmaceutical companies are crucial for translating these findings into tangible medical breakthroughs.

The regulatory landscape for novel compounds like 6-(Azepan-2-yl)quinoline is stringent but well-established, ensuring that only safe and effective drugs reach patients. Regulatory agencies require comprehensive data on chemical composition, pharmacokinetics, toxicology, and clinical efficacy before approving a new drug candidate. The rigorous testing process underscores the importance of thorough research and development before commercialization.

Future directions in the study of 6-(Azepan-2-yl)quinoline include exploring its potential in combination therapies with other drugs to maximize therapeutic benefits while minimizing side effects. Additionally, investigating its role in preclinical models will provide further evidence of its clinical relevance. The integration of artificial intelligence (AI) into drug discovery processes has accelerated the identification of promising candidates like this one, offering hope for faster development cycles.

The impact of 6-(Azepan-2-yl)quinoline extends beyond academic research; it represents a significant step forward in addressing unmet medical needs. As our understanding of disease mechanisms evolves, compounds like this one will continue to play a pivotal role in developing innovative treatments. The interdisciplinary nature of modern pharmaceutical research ensures that advancements are made collaboratively across various scientific disciplines.

In conclusion,6-(Azepan-2-yl)quinoline (CAS No. 904816-03-1) is a structurally unique compound with immense potential in pharmaceutical applications. Its synthesis, pharmacological properties, and future prospects highlight its importance as a scaffold for drug development. Continued research efforts will likely uncover even more about its capabilities and contribute to improving global health outcomes.

• 527673-86-5(5-AZEPAN-2-YL-QUINOLINE)
• 1355225-87-4(6-(1-Butylpiperidin-2-yl)quinoline)
• 108831-50-1(4-(pyrrolidin-2-yl)quinoline)
• 1337017-80-7(7-(piperidin-2-yl)quinoline)
• 847248-34-4(Quinoline, 6-(1-methyl-2-pyrrolidinyl)-)
• 847248-46-8(PYRROLIDINIUM, 1,1-DIMETHYL-2-(6-QUINOLINYL)-, IODIDE)
• 956108-19-3(956108-19-3)
• 1337214-15-9(7-(PYRROLIDIN-2-YL)QUINOLINE)
• 1270520-09-6(4-(piperidin-2-yl)quinoline)
• 860299-05-4(6-(pyrrolidin-2-yl)quinoline)